Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
Key Highlights
- ➤PTC-2105 25 mg/kg significantly increased overall survival versus saline controls (p = 0.0142)
- ➤Speedy exceeded 167 weeks, outliving every saline control by more than 20%
- ➤PTC-2105 exceeded semaglutide’s weight loss after about 30 weeks while increasing lean mass
- ➤Pulmatrix stockholders vote October 26 on merger expected to create Nasdaq-listed MTXL
- ➤Eos plans Phase 1b PTC-2105 study in adults aged 60 and older with sarcopenia
Expert Statements
Kevin Slawin, Founder and CEO of Eos SENOLYTIX
“The goal of geroscience is not simply more years, but more healthy years.”
Kevin Slawin, Founder and CEO of Eos SENOLYTIX
“What we presented today is a body of evidence, gathered the slow way in naturally aged animals followed until their natural death, which showed that targeting mitochondrial decline and senescent cells together can improve both healthspan and lifespan in mice. Our next step is to find out whether these benefits carry over to older adults, starting in older individuals with sarcopenia.”
Kevin Slawin, Founder and CEO of Eos SENOLYTIX
“Speedy is a single animal, but he is an approachable way into the full dataset behind him.”
Kevin Slawin, Founder and CEO of Eos SENOLYTIX
“In a field with a lot of noise, we think the best way to earn attention is to let people watch the science happen and judge it for themselves.”
* In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) * “Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night * New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts
BERLIN and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”) a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and mechanism-of-action data for its lead candidate, PTC-2105, in an Industry Keynote Address at the 17th World Congress on Targeting Mitochondria 2026 in Berlin. The keynote, “Building on the Foundation of Four: Advancing Mitochondrial-Targeted Geropeptide Medicine,” delivered by Dr. Kevin Slawin, Founder and CEO of Eos SENOLYTIX, acknowledged the contribution of Dr. Hazel Szeto, who with Dr. Peter Schiller co-discovered the four amino acid peptide, SS-31, (“elamipretide”), the first FDA-approved therapeutic that directly targets mitochondria. Dr. Szeto opened the session, Two Perspectives on Mitochondrial Medicine, with the academic keynote; the pair then joined a panel discussion immediately afterwards.
Get started
Create a free account to read the full story.